ZIDOVUDINE FOR THE PREVENTION OF VERTICAL HIV TRANSMISSION - A DECISION-ANALYTIC APPROACH

被引:0
作者
ROUSE, DJ
OWEN, J
GOLDENBERG, RL
VERMUND, SH
机构
[1] UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294
[2] UNIV ALABAMA,DEPT PEDIAT,BIRMINGHAM,AL
[3] UNIV ALABAMA,DEPT EPIDEMIOL,BIRMINGHAM,AL
来源
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY | 1995年 / 9卷 / 04期
关键词
CONGENITAL HIV; ZIDOVUDINE; DECISION ANALYSIS;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The purpose of this study was to quantify the benefits of maternal-neonatal zidovudine (ZDV) administration for the prevention of vertical human immunodeficiency virus (HIV) transmission against the potential risks of drug-induced complications in uninfected children. A decision analysis model was created with use of a Markov cohort simulation, for evaluating both survival and quality of life for two hypothetical cohorts of HIV-exposed neonates: one with in utero and neonatal exposure to preventive ZDV therapy and the other not exposed. The model included the probability of congenital HIV infection with and without ZDV treatment (estimates derived from AIDS Clinical Trials Group study 076), the yearly probability of death with and without congenital HIV infection, a range of probabilities of adverse effects from ZDV use, and a range of ages in life when any adverse effect would manifest. In a series of scenarios, the impact of different estimates for the quality-of-life decrement from any adverse ZDV effect in HIV-uninfected children was assessed, and threshold values for this estimate were established, i.e., critical values below which withholding ZDV would be the preferred choice. Across a wide range of estimates for multiple contingencies, ZDV use was associated with a greater number of quality-adjusted life years than was non-use. Only in implausible, pessimistic scenarios (i.e., a high incidence of profound adverse effects beginning early in life) would withholding ZDV be the rational choice for an asymptomatic HIV-infected pregnant woman. This analysis supports recent recommendations that ZDV be offered to all HIV-infected pregnant women (and their neonates) who meet the inclusion criteria of AIDS Clinical Trials Group study 076 to prevent vertical HIV transmission.
引用
收藏
页码:401 / 407
页数:7
相关论文
共 50 条
  • [41] A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions
    Ehteshami-Afshar, Solmaz
    Zafari, Zafar
    Hamidi, Nima
    FitzGerald, J. Mark
    Lynd, Larry
    Sadatsafavi, Mohsen
    VALUE IN HEALTH, 2019, 22 (09) : 1070 - 1082
  • [42] A DECISION-ANALYTIC CONCEPT SELECTION FOR A COMMERCIAL SYSTEM USING OBJECTIVE DATA TO MODEL UNCERTAINTY
    Takai, Shun
    Razu, Swithin S.
    Banga, Karan
    PROCEEDINGS OF THE ASME INTERNATIONAL DESIGN ENGINEERING TECHNICAL CONFERENCES AND COMPUTERS AND INFORMATION IN ENGINEERING CONFERENCE, VOL 8, PTS A AND B, 2010, : 157 - 166
  • [43] Assessing the sensitivity of decision-analytic results to unobserved markers of risk: Defining the effects of heterogeneity bias
    Kuntz, KM
    Goldie, SJ
    MEDICAL DECISION MAKING, 2002, 22 (03) : 218 - 227
  • [44] Vertical Transmission of HIV-An Update
    Lala, Mamatha M.
    Merchant, Rashid H.
    INDIAN JOURNAL OF PEDIATRICS, 2010, 77 (11) : 1270 - 1276
  • [45] Simple Decision-Analytic Functions of the AUC for Ruling Out a Risk Prediction Model and an Added Predictor
    Baker, Stuart G.
    MEDICAL DECISION MAKING, 2018, 38 (02) : 225 - 234
  • [46] Transmission of zidovudine resistant strains of HIV-1: the first wave
    Blower, S
    AIDS, 2001, 15 (17) : 2317 - 2318
  • [47] Evaluation of Markers and Risk Prediction Models: Overview of Relationships between NRI and Decision-Analytic Measures
    Van Calster, Ben
    Vickers, Andrew J.
    Pencina, Michael J.
    Baker, Stuart G.
    Timmerman, Dirk
    Steyerberg, Ewout W.
    MEDICAL DECISION MAKING, 2013, 33 (04) : 490 - 501
  • [48] Modeling the coronavirus disease 2019 pandemic: A comprehensive guide of infectious disease and decision-analytic models
    Mac, Stephen
    Mishra, Sharmistha
    Ximenes, Raphael
    Barrett, Kali
    Khan, Yasin A.
    Naimark, David M. J.
    Sander, Beate
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2021, 132 : 133 - 141
  • [49] Adequacy of prenatal care and prescription of zidovudine to prevent perinatal HIV transmission
    Lansky, A
    Jones, JL
    Burkham, S
    Reynolds, K
    Bohannon, B
    Bertolli, J
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 21 (03) : 223 - 227
  • [50] Oral zidovudine during labor to prevent perinatal HIV transmission, Bangkok: tolerance and zidovudine concentration in cord blood
    Bhadrakom, C
    Simonds, RJ
    Mei, JV
    Asavapiriyanont, S
    Sangtaweesin, V
    Vanprapar, N
    Moore, KHP
    Young, NL
    Hannon, WH
    Mastro, TD
    Shaffer, N
    AIDS, 2000, 14 (05) : 509 - 516